C. R. Bard boosts bottom line for full-year 2007 and Q4.

C. R. Bard, Inc., based in Murray Hill, NJ, posted gains for its fourth quarter and fiscal year 2007. The company reported net sales of $583 million, an increase of 12% compared to 2006. For the quarter, net sales in the United States were $394 million, while international sales were $190 million, increases of 9% and 19%, respectively. Net sales for the full year 2007 were $2.2 billion, an increase of 11%.

For the overall 2007 fiscal year, income from continuing operations was $406 million and diluted earnings per share were $3.84, an increase of 29% and 31% respectively, compared with 2006.

"We are pleased to conclude our centennial year with solid fourth-quarter and full-year results," said Timothy M. Ring, chairman and CEO. "Our 2007 performance marks the fifth consecutive year that Bard has delivered adjusted EPS ]earnings per share] growth above the company's target of 14%. This success demonstrates the effectiveness of our strategy, and the ability of our organization to execute. We look forward to making 2008 another successful year for Bard and its shareholders."

C. R. Bard develops medical technology in the fields of vascular, urology, oncology and surgical specialty products.

C. R. Bard concludes its 100th year in business with significant growth in sales and profit for fiscal year 2007